

## Certificate of Analysis

### MKK6/SKK3, unactive

(Recombinant enzyme expressed in *E.coli* cells)

Item # 14-304, 14-304-K, 14-304M

Parent Lot # 1604418

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

**Product Description:** N-terminal maltose binding protein tagged, recombinant MKK6 amino acids 4-end, expressed in *E.coli* cells. Purified using amylase agarose. Purity 99% by SDS-PAGE and Coomassie blue staining. MW = 80kDa.

#### Specific Activity (Parent lot# 1604418):

As provided, this lot demonstrated 3% of maximum activity. Activated by phosphorylation with MEKK (cat# 14-196).

**Formulation:** 3.19mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij-35, 20% glycerol. Frozen solution.

**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

Activation Assay: 4µM MKK6, unactive was activated using 200µg/ml MEKK (Catalogue# 14-196) which in turn was used to activate 2µM SAPK2a, and the increased activity against MBP determined. The activation and assay are described on pages two and three. Results of this assay are shown below.

Active MEKK	Unactive MKK6	Mean cpm	Comments
5µg	8.06µg	20658	Kinase activity
None	8.06µg	914	Background

MS Tryptic Fingerprint: Confirmed product identity as MKK6 with the translated sequence listed on page four



DS-PAGE and Coomassie Stain: Purity was assessed by SDS-PAGE and Coomassie blue staining using 3µg of MKK6, unactive.

# Certificate of Analysis

## Kinase Assay Protocol

### Stock Solutions

1. **10 x Activation Buffer:** 500mM Tris/HCl pH7.5, 1mM EGTA, 1% 2-mercaptoethanol, 1mM Na<sub>3</sub>VO<sub>4</sub>, 10mg/ml BSA.
2. **10 x Reaction Buffer:** 250mM Tris/HCl pH7.5, 1mM EGTA.
3. **Enzyme Dilution Buffer:** 50mM Tris/HCl pH7.5, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.1mM Na<sub>3</sub>VO<sub>4</sub>, 1mg/ml BSA.
4. **5 x Mg/ATP (Stages One and Two):** 50mM MgAc, 0.5mM ATP.
5. **MEKK:** Use at a final assay concentration of 200µg/ml. Prepare a 1mg/ml stock. Use 5µl of stock per assay point.
6. **MKK6 unactive:** Use at a final assay concentration of 4µM (0.322mg/ml). Prepare a 1mg/ml stock. Use 8µl of stock per assay point.
7. **SAPK2a unactive:** Use at a final assay concentration of 2µM (0.135mg/ml). Prepare a 0.675mg/ml stock. Use 5µl of stock per assay point.
8. **MBP:** Use at a final assay concentration of 0.33mg/ml. Prepare a 3.33mg/ml stock. Use 2.5µl of stock per assay point.
9. **[γ-<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[γ-<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ-<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

### Assay Procedure:

#### **Stage One: Activation of MKK6 by MEKK**

1. Add 2.5µl of 10 x activation buffer to a microcentrifuge tube.
2. Add 5µl of **MEKK**.
3. Add **8µl MKK6, unactive**.
4. Add 4.5µl of dH<sub>2</sub>O.
5. Add 5µl of stage one Mg/ATP mixture. (In appropriate controls add dilution buffer to a final volume of 25µl).
6. Incubate for 1 hour at 30°C.
7. Stop the reaction by diluting the MKK6 250-1000 fold and storing on ice.

#### **Stage Two: Activation of SAPK2a by MKK6**

1. Add 2.5µl of 10 x activation buffer to a microcentrifuge tube.
2. Add 5µl of **SAPK2a unactive**.
3. Add **2.5µl diluted MKK6 (activated) from Stage One**.
4. Add 10µl of dH<sub>2</sub>O.
5. Add 5µl of stage two Mg/ATP mixture.
6. Incubate at 30°C for 15 minutes
7. Stop reaction by immediately transferring 5µl into **Stage Three** reaction mixture.

## Certificate of Analysis

### **Stage Three: Phosphorylation of MBP by SAPK2a**

1. Add 2.5 $\mu$ l of reaction buffer to a microcentrifuge tube.
2. Add 2.5 $\mu$ l of **MBP**.
3. Add 5 $\mu$ l of **activated SAPK2a from Stage Two**.
4. Add 5 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of the diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 15 minutes at 30°C.
7. Transfer a 20 $\mu$ l aliquot onto the centre of a 2cm x 2cm **P81** paper square.
8. Wash the assay squares twice for 5 minutes with 75mM phosphoric acid.
9. Wash the assay squares once for 2 minutes with acetone.
10. Transfer the assay squares to a vial and add 1ml scintillation cocktail.
11. Read in scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

# Certificate of Analysis

## MKK6 (4-end) Sequence Information

<u>Protein</u>	human MKK6 (4-end)
<u>Tags</u>	N-terminal maltose binding protein
<u>Native sequence</u>	S396 of the recombinant protein is equivalent to S4 of human MKK6
<u>Accession number</u>	EMBL U39657

### Recombinant MKK6 amino acid sequence:

1 MKTEEGKLVI WINGDKGYNG LAEVGKKFEK DTGIKVTVEH PDKLEEKFPQ VAATGDGPDI  
61 IFWAHDHRFGG YAQSGLLAEI TPDKAQDQL YPFTWDAVRY NGKLIAYPIA VEALSLIYNK  
121 DLLPNPPKTW EEIPALDKEL KAKGKSALMF NLQE PYFTWP LIAADGGYAF KYENGKYDIK  
181 DVGVNDAGAK AGLTFLVDLI KNKHMNADTD YSIAEAAFNK GETAMTINGP WAWSNIDTSK  
241 VNYGVTVLPT FKGQPSKPFV GVL SAGINAA SPNKE LAKEF LENYLLTDEG LEAVN KDKPL  
301 GAVALKSYEE ELAKDPRIA TMENA QKGEI MPNIPQMSAF WYAVRTAVIN AASGRQTVD  
361 ALKDA QTNSS SNNNNNNNNN NLGIEGRISE FGSSRSKGKK RNPGLKIPKE AFEQPQTSS  
421 PPRDLDSKAC ISIGNQNFEV KADDLEPIME LRGAYGVVE KMRHVPSGQI MAVKRIRATV  
481 NSQE QKRLLM DLDISMRTVD CPFTVTFYGA LFREGDVWIC MELMDTSLDK FYKQVIDKGQ  
541 TIPE DILGKI AVSIVKALEH LHSKLSVIHR DVKPSNVLIN ALGQVKMDF GISGYLVDSV  
601 AKTIDAGCKP YMAPERINPE LNQKGYSVKS DIWSLGITMI ELAILRFPYD SWGTPFQQLK  
661 QVVEEPSPQL PADKFSAEFV DFTSQCLKKN SKERPTYPEL MQHPFFT LHE SKGTDVASFV  
721 KLILGD

### Recombinant MKK6 nucleotide sequence:

1 atgaaaactg aagaaggtaa actggtaatc tggattaacg gcgataaaagg ctataacgg  
61 ctcgctgaag tcggtaagaa attcgagaaa gataccggaa ttaaagtca cgtt gagcat  
121 ccggataaaac tggaaagagaa attcccacag gttcggcaa ctggcgtatgg ccctgacatt  
181 atcttctggg cacacgaccg ctttgggtggc tacgctcaat ctggcctgtt ggctgaaatc  
241 acccccggaca aagcgttcca ggacaagctg tatccgttta cctggatgc cgtacgttac  
301 aacggcaagc tgattgctta cccgatcgct gttgaagctg tatcgtat ttataacaaa  
361 gatctgctgc cgaacccgccc aaaaacctgg gaagagatcc cggcgttggaa taaagaactg  
421 aaagcgaaag gtaagagcgc gctgtatgttc aacctgcaag aaccgtactt cacctggccg  
481 ctgattgctg ctgacggggg ttatgcgttca aagtatgaaa acggcaagta cgacattaaa  
541 gacgtggcgc tggataacgc tggcgcggaa gcgggtctga ctttccgtt tgacgttgc  
601 aaaaacaaac acatgaatgc agacaccgt tactccatcg cagaagctgc cttaataaaa  
661 ggcgaaacag cgatgaccat caacggcccg tggcatggt ccaacatcg aaccaggaaaa  
721 gtgaatttatg gtgtacggt actggcgcacc ttcaagggtc aaccatccaa accgttcgtt  
781 ggcgtgctga gcgcaggat taacgcgc agtccgaaca aagagctggc aaaagagttc  
841 ctcgaaaact atctgctgac tggatggat ctggaaagcgg ttaataaaa caaaccgtgc  
901 ggtgccgttag cgctgaagtc ttacgaggaa gagttggcga aagatccacg tattggcc  
961 accatggaaa acgcccagaa aggtgaaatc atgcgcgaaca tccgcagat gtccgc  
1021 tggatgcgc tgctgactgc ggtgatcaac gcccgcagcg gtcgtcagac tgcgtatgaa  
1081 gcccgtaaag acgcgcagac taattcgagc tcgaacaaca acaacaataa caataacaac  
1141 aacatcgaaa tcgaggaa gatttcagaa ttccggatccct ctagatcgaa aggcaagaag  
1201 cggaaaccctg gccttaaaat tccaaaagaa gcatttgcac aacccatcgac cagttccaca  
1261 ccacctcgag atttagactc caaggcttgc atttcttattt gaaatcgaa ctttgagg  
1321 aaggcagatg acctggagcc tataatggaa ctgggacgag gtgcgtacgg ggtgggtggag  
1381 aagatgcggc acgtgcccag cggcagatc atggcgttgc agcggatccg agccacagta  
1441 aatagccagg aacagaaaacg gctactgtat gatttggata tttccatgag gacgggtggac  
1501 tgtccattca ctgtcaccc ttatggcga ctgtttcggg agggatgtt gttggatctgc  
1561 atggagctca tggatacatc actagataaaa ttctacaaac aagttattga taaaggccag

## Certificate of Analysis

```
1621 acaattccag aggacatctt agggaaaata gcagttcta ttgtaaaagc attagaacat  
1681 ttacatagta agctgtctgt cattcacaga gacgtcaagc cttctaattgt actcatcaat  
1741 gctctcggtc aagtgaagat gtgcgatttt ggaatcagtg gctacttggt ggactctgtt  
1801 gctaaaacaa ttgatgcagg ttgcaaacca tacatggccc ctgaaagaat aaaccagag  
1861 ctcaaccaga agggatacag tgtgaagtct gacatttgga gtctggcat cacgatgatt
```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 **Eurofins Pharma Discovery Services UK Limited** is an independent member of Eurofins Discovery Services